Redsense Medical (REDS) Q4 2025 earnings summary

Executive summary

• 2025 was a year of restructuring, focusing on operational efficiency and long-term execution, with improved systems and alignment between sales and production.

• Sales volumes remained broadly in line with the previous year, with increased U.S. end-customer sales, despite external challenges such as logistics, currency effects, and geopolitical uncertainty.

• The company shifted to a more consistent, demand-driven sales approach, reducing quarter-driven volatility.

Financial highlights

• Net sales for Q4 2025 were KSEK 6,035, down 52% year-over-year; full-year net sales were KSEK 24,023, a 15% decrease.

• Operating loss (EBIT) for Q4 was KSEK -1,952 (vs. 5,525 last year); full-year EBIT was KSEK -7,366 (vs. 210 last year).

• Result after tax for Q4 was KSEK -1,844 (vs. 5,629); full-year result after tax was KSEK -7,172 (vs. 342).

• Earnings per share for Q4 were SEK -0.11 (0.34); full-year EPS was SEK -0.44 (0.02).

• Gross margin for Q4 was 52% (vs. 64%); full-year gross margin was 53% (vs. 62%).

• Cash and cash equivalents at year-end were KSEK 7,356 (vs. 15,356).

Outlook and guidance

• A revised pricing structure will be implemented in February 2026 to improve margin stability and support broader adoption.

• Priorities for 2026 include disciplined growth in the U.S., market introduction of the Redsense Clamp, and expansion into selected new markets.

• Achieving U.S. regulatory clearance for the Clamp is a top priority for 2026.